Journey Medical Corporation (NASDAQ:DERM) Receives $13.00 Consensus PT from Brokerages

Posted by on May 28th, 2026

Journey Medical Corporation (NASDAQ:DERM – Get Free Report) has earned a consensus recommendation of “Hold” from the four brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and two have issued a buy recommendation on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $13.00.

Several equities analysts have commented on the company. HC Wainwright reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Journey Medical in a research report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Journey Medical in a research report on Monday, April 20th.

Read Our Latest Research Report on Journey Medical

Journey Medical Stock Performance

NASDAQ DERM opened at $5.99 on Thursday. The company has a market cap of $164.90 million, a P/E ratio of -16.19 and a beta of 1.03. The business’s 50 day moving average price is $5.54 and its 200-day moving average price is $7.16. Journey Medical has a fifty-two week low of $4.31 and a fifty-two week high of $9.56. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.47 and a current ratio of 1.72.

Journey Medical (NASDAQ:DERM – Get Free Report) last issued its quarterly earnings results on Wednesday, May 13th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). Journey Medical had a negative return on equity of 35.57% and a negative net margin of 14.82%.The company had revenue of $15.96 million during the quarter, compared to the consensus estimate of $15.47 million. Sell-side analysts predict that Journey Medical will post 0.17 earnings per share for the current year.

Institutional Trading of Journey Medical

Several hedge funds and other institutional investors have recently bought and sold shares of DERM. Jane Street Group LLC bought a new stake in Journey Medical during the 1st quarter valued at $110,000. Geode Capital Management LLC lifted its position in shares of Journey Medical by 130.7% during the second quarter. Geode Capital Management LLC now owns 262,353 shares of the company’s stock valued at $1,884,000 after buying an additional 148,612 shares during the last quarter. Creative Planning lifted its position in shares of Journey Medical by 178.5% during the second quarter. Creative Planning now owns 32,764 shares of the company’s stock valued at $235,000 after buying an additional 21,000 shares during the last quarter. JPMorgan Chase & Co. purchased a new stake in shares of Journey Medical during the second quarter valued at about $41,000. Finally, New York State Common Retirement Fund purchased a new stake in shares of Journey Medical during the second quarter valued at about $103,000. Institutional investors own 7.25% of the company’s stock.

About Journey Medical

(Get Free Report)

Journey Medical Corp, headquartered in Fairfield, New Jersey, is a commercial dermatology company focused on acquiring, developing and marketing prescription dermatology products in the United States. Since its incorporation in 2019, the company has built a portfolio of both branded and generic topical therapies designed to address a range of skin conditions, including acne, atopic dermatitis, fungal infections and inflammatory lesions.

The company’s product lineup features antibiotic/anti-inflammatory combinations and corticosteroid-based formulations delivered through proprietary gel, cream and foam vehicles.

Featured Articles

Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.